Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05GJW
|
|||
| Former ID |
DAP000565
|
|||
| Drug Name |
Cladribine
|
|||
| Synonyms |
Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribina; Cladribinum; CldAdo; Leustat; Leustatin; Litak; Movectro;Mylinax; CL9; RWJ 26251; Leustatin (TN); RWJ-26251; Cladribine [USAN:INN:BAN]; RWJ-26251-000; Cladribine (JAN/USAN/INN); Leustatin, 2-chlorodeoxyadenosine, Cladribine; Adenosine, 2-chloro-2'-deoxy; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2 Chlorodeoxyadenosine; 2'-Deoxy-2-chloroadenosine; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine; 2-chloro-deoxyadenosine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hairy cell leukaemia [ICD-11: 2A82.2; ICD-10: C91.4; ICD-9: 202.4] | Approved | [1], [2] | |
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 3 | [3] | ||
| Relapsing-remitting multiple sclerosis [ICD-11: 8A40.0] | Phase 3 | [4] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
EMD Serono Rockland, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12ClN5O3
|
|||
| Canonical SMILES |
C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
|
|||
| InChI |
1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
|
|||
| InChIKey |
PTOAARAWEBMLNO-KVQBGUIXSA-N
|
|||
| CAS Number |
CAS 4291-63-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
610461, 855756, 866156, 7848433, 7978577, 7978957, 8165006, 14799875, 14897807, 26719669, 26757803, 29287787, 46386544, 46504588, 48415788, 49865077, 49903916, 49903918, 50104045, 50446026, 56312468, 56312469, 56312470, 56312853, 56422184, 57309572, 57330593, 71821359, 87323981, 92308638, 92713835, 99218181, 99431527, 99437023, 103602769, 104350170, 118046705, 124659094, 124757075, 124800053, 124886798, 124886799, 125163879, 126624559, 126655830, 128966217, 131314655, 134337856, 134984314, 135683425
|
|||
| ChEBI ID |
CHEBI:567361
|
|||
| ADReCS Drug ID | BADD_D00479 | |||
| SuperDrug ATC ID |
L01BB04
|
|||
| SuperDrug CAS ID |
cas=004291638
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
|
Studied Microbe: Listeria welshimeri serovar 6b str. SLCC5334
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Metabolic Reaction | Hydrolysis | |||
| Metabolic Effect | Decrease activity | |||
| Description | Cladribine can be metabolized by Listeria welshimeri serovar 6b str. SLCC5334 through hydrolysis, which results in the decrease of the drug's activity. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli Nissle 1917
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Metabolic Reaction | Hydrolysis | |||
| Metabolic Effect | Decrease activity | |||
| Description | Cladribine can be metabolized by Escherichia coli Nissle 1917 through hydrolysis, which results in the decrease of the drug's activity. | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Cladribine (adjusted p-values: 4.32E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Cladribine (adjusted p-values: 4.80E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli IAI1 was decreased by Cladribine (adjusted p-values: 1.73E-05). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine deaminase (ADA) | Target Info | Inhibitor | [7], [8] |
| BioCyc | Purine nucleotides degradation | |||
| Purine deoxyribonucleosides degradation | ||||
| Purine ribonucleosides degradation to ribose-1-phosphate | ||||
| Adenosine nucleotides degradation | ||||
| Superpathway of purine nucleotide salvage | ||||
| Adenine and adenosine salvage III | ||||
| KEGG Pathway | Purine metabolism | |||
| Metabolic pathways | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Pathwhiz Pathway | Purine Metabolism | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| C-MYB transcription factor network | ||||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| Validated transcriptional targets of TAp63 isoforms | ||||
| Reactome | Purine salvage | |||
| WikiPathways | Metabolism of nucleotides | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4799). | |||
| REF 2 | Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015 Sep 29;5:14554. | |||
| REF 6 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 7 | Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57. | |||
| REF 8 | Cladribine. Ortho Biotech Inc. Curr Opin Investig Drugs. 2001 Dec;2(12):1751-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.